Table 2 Univariable and multivariable analysis of 562 LNN breast cancer patients (METABRIC dataset [13]) used to examine prognostic value of EMAT subtype designation status for 10-year follow-up
Univariable analysis | Multivariable (age, tumor size, grade, IHC status**, any chemo/hormonal/ radiation therapy) | Multivariable (age, tumor size, grade, PAM50 status#, any chemo/hormonal/ radiation therapy) | Multivariable (age, tumor size, grade, EMAT status##, any chemo/hormonal/ radiation therapy) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | P | HR (95% CI) | n | P | HR (95% CI) | n | P | HR (95% CI) | n | P | HR (95% CI) | |
Age | 562 | 0.70 | 1.00 (0.99–1.02) | 510 | 0.18 | 1.014 (0.99–1.03) | 521 | 0.21 | 1.01 (0.99–1.03) | 521 | 0.21 | 1.01 (0.99–1.03) |
Tumor size (< 2, 2–5, > 5) | 559 | 0.02 | 1.67 (1.10–2.54) | 510 | 0.04 | 1.59 (1.04–2.45) | 521 | 0.03 | 1.60 (1.04–2.49) | 521 | 0.04 | 1.59 (1.03–2.47) |
Tumor grade* | 524 | 0.20 | 1.26 (0.89–1.79) | 510 | 0.46 | 1.16 (0.78–1.71) | 521 | 0.45 | 1.16 (0.78–1.73) | 521 | 0.98 | 1.01 (0.69–1.47) |
Any chemotherapy | 562 | 0.15 | 1.78 (0.82–3.87) | 510 | 0.17 | 1.86 (0.78–4.451) | 521 | 0.12 | 1.99 (0.84–4.77) | 521 | 0.10 | 2.07 (0.87–4.92) |
Any hormonal therapy | 562 | 0.15 | 0.72 (0.46–1.12) | 510 | 0.06 | 0.62 (0.38–1.01) | 521 | 0.04 | 0.60 (0.37–0.97) | 521 | 0.05 | 0.62 (0.39–1.00) |
Any radiation therapy | 562 | 0.20 | 0.76 (0.50–1.16) | 510 | 0.28 | 0.78 (0.50–1.22) | 521 | 0.24 | 0.77 (0.49–1.19) | 521 | 0.15 | 0.72 (0.46–1.12) |
IHC status** | 538 | 0.03 | 1.23 (1.02–1.47) | 510 | 0.32 | 1.11 (0.90–1.37) | ||||||
PAM50 status# | 562 | 0.12 | 1.14 (0.97–1.35) | 521 | 0.67 | 1.04 (0.86–1.27) | ||||||
EMAT status## | 562 | 1E−4 | 1.65 (1.29–2.11) | 521 | 3E−4 | 1.64 (1.25–2.14) | ||||||